CIK 0001652130 · Large accelerated filer
Intellia Therapeutics, Inc.
Sign in to watch- Ticker
- NTLA
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 364785571
- Phone
- 857-285-6200
- Business address
- 400 TECHNOLOGY SQUARE, SUITE 100, CAMBRIDGE, MA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $417,899
- in 3 filings, $395K under 10b5-1 plans
Net −$417,899. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 7 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-06-12 | Cohen Fred E Director | Grant or award | +7,737 | 49,453 | ||
| 2024-06-12 | Cohen Fred E Director | Grant or award · Stock Option (right to buy) | +11,515 | 11,515 | ||
| 2024-06-12 | Bhanji Muna Director | Grant or award | +7,737 | 19,733 | ||
| 2024-06-12 | Bhanji Muna Director | Grant or award · Stock Option (right to buy) | +11,515 | 11,515 | ||
| 2024-06-12 | CHASE WILLIAM J Director | Grant or award | +7,737 | 26,693 | ||
| 2024-06-12 | CHASE WILLIAM J Director | Grant or award · Stock Option (right to buy) | +11,515 | 11,515 | ||
| 2024-03-04 | BASTA JAMES EVP, General Counsel | Sale | −2,297 | $32.99 | $76K | 81,571 |
| 2024-03-04 | Clark Eliana EVP, Chief Technical Officer | Sale | −605 | $32.99 | $20K | 71,470 |
| 2024-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award | +37,966 | 81,893 | ||
| 2024-03-01 | Sepp-Lorenzino Laura EVP, Chief Scientific Officer | Grant or award · Stock Option (right to buy) | +54,794 | 54,794 | ||
| 2024-03-01 | BASTA JAMES EVP, General Counsel | Grant or award | +32,394 | 83,868 | ||
| 2024-03-01 | BASTA JAMES EVP, General Counsel | Grant or award · Stock Option (right to buy) | +46,752 | 46,752 | ||
| 2024-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award | +38,701 | 93,073 | ||
| 2024-03-01 | Lebwohl David EVP, Chief Medical Officer | Grant or award · Stock Option (right to buy) | +55,855 | 55,855 | ||
| 2024-03-01 | Hicks Derek EVP, Chief Business Officer | Grant or award | +29,393 | 66,380 | ||
| 2024-03-01 | Hicks Derek EVP, Chief Business Officer | Grant or award · Stock Option (right to buy) | +42,421 | 42,421 | ||
| 2024-03-01 | Clark Eliana EVP, Chief Technical Officer | Grant or award | +31,230 | 72,075 | ||
| 2024-03-01 | Clark Eliana EVP, Chief Technical Officer | Grant or award · Stock Option (right to buy) | +45,072 | 45,072 | ||
| 2024-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award | +28,628 | 69,213 | ||
| 2024-03-01 | Goddard Glenn EVP, Chief Financial Officer | Grant or award · Stock Option (right to buy) | +41,316 | 41,316 |
Page 7 of 40 · 783 trades